Benitec Biopharma Ltd (BNTC)

[Blane]

Post on Hotcopper regarding TT-034 by poster J8.

"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437581/

In this link on page 22, the author discusses TT-034 with regard to clinically feasible doses. It is interesting to note that there is reason to believe that a lower end dose could start a response. The replicon model carries thousands of copies of the virus, while a human has 5-7 copies per cell. Lower toxicity of TT-034 when compared to its predecessor produces less shRNAs but provides better transduction. There is a section there too that states all liver tissues were transduced. We won't need too many shRNAs being delivered per cell to rid it of five or seven copies of HCV. I suppose there is a a possibility of a surprise response!"


While the details of this post is not necessarily expected, it would definitely be a nice and understandable surprise.